Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Hepatitis tóxica asociada al uso de tamoxifeno.Presentación de un caso y revis...
Información de la revista
Vol. 25. Núm. 4.
Páginas 247-250 (Enero 2002)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 25. Núm. 4.
Páginas 247-250 (Enero 2002)
Acceso a texto completo
Hepatitis tóxica asociada al uso de tamoxifeno.Presentación de un caso y revisión bibliográfica
Toxic hepatitis associated with tamoxifene use. a case report and literature review
Visitas
21605
M.C. Lasso de la Vegaa,
Autor para correspondencia
lasso_mca@gva.es

Correspondencia: Dr. M.C. Lasso de la Vega Girona. Unidad de Farmacología Clínica. Hospital General Universitario de Alicante. Maestro Alonso, 109. 03010 Alicante.
, P. Zapatera, J. Suchb, J. Sola-Verab, A. Payác, J.F. Horgaa, M. Pérez-Mateob
a Unidad de Farmacología Clínica. Hospital General Universitario de Alicante
b Unidad Hepática. Servicios de Medicina Hospital General Universitario de Alicante
c Unidad Hepática. Anatomía Patológica. Hospital General Universitario de Alicante
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

El tamoxifeno es un agente antiestrogénico que actúa uniéndose al receptor de estrógenos y se usa como tratamiento coadyuvante en cánceres de mama avanzados que expresan dicho receptor. Ensayos clínicos realizados con tamoxifeno han demostrado su eficacia hasta los 5 años de tratamiento al reducir tanto la mortalidad como las recidivas. Se ha descrito una serie de casos de hepatotoxicidad asociados al uso de tamoxifeno, que incluyen colestasis con o sin citólisis y esteatohepatitis. Presentamos el caso de una paciente que desarrolló un cuadro de afección hepática durante el tratamiento continuado con tamoxifeno, revisamos la información publicada hasta el momento y discutimos la conveniencia de continuar o suspender el tratamiento en función del cuadro de hepatotoxicidad y del tiempo de tratamiento con tamoxifeno.

Abstract

Tamoxifen is an antiestrogenic drug that acts by binding to the estrogen receptor. The drug is used as a co-adjuvant treatment in advanced breast cancer expressing the oestrogen-receptor protein. Clinical trials of tamoxifen have shown its efficacy in reducing mortality and recurrence rates over a five-year treatment. Cases of tamoxifen-associated hepatotoxicity have been described, including cholestasis with or without cytolysis and steatohepatitis. We report the case of a female patient who developed hepatic alterations while undergoing continuous tamoxifen treatment. We also present an overview of similar cases published to date and comment on the advisability of continuing or suppressing this treatment in patients with hepatotoxicity or after a five-year treatment period.

El Texto completo está disponible en PDF
Bibliografía
[1.]
Early Breast Cancer Trialists' Collaboative Group.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75.000 women.
Lancet, 339 (1992), pp. 1-18
[2.]
C.K. Osborne.
Drug therapy: tamoxifen in the treatment of breast cancer.
N Engl J Med, 26 (1998), pp. 1609-1618
[3.]
C.L. Willians, G.M. Stancel.
Estrogens and progestins.
Goodman and Gilman's the farmacological basis of therapeutics (9th ed.), pp. 1411-1440
[4.]
C.K. Ching, P.G. Smith, R.G. Long.
Tamoxifen-associated hepatocellular damage and agranulocytosis.
Lancet, 339 (1992), pp. 940
[5.]
H.C. Cotez-Pinto, A. Baptista, M.E. Camilo, E.B. de Costa, A. Valente, M. Caraneiro de Moura.
Tamoxifen-associated steatohepatitis-report of three cases.
J Hepatology, 23 (1995), pp. 95-97
[6.]
M. Biour, R. Poupon, J. Grangé, O. Chazouillères, P. Jaillon.
Hépatotoxicité des médicaments.
Gastroentl Clin Biol, 23 (1999), pp. 1310-1352
[7.]
F.E. Karch, M.D. Lassagna.
Toward the operational identification of adverse drug reactions.
Clin Pharmacol Ther, 21 (1997), pp. 247-254
[8.]
C. Bénichou.
Criteria of drug-induced liver disorders. Report of an International Consensus Meeting.
J Hepatol, 11 (1990), pp. 272-276
[9.]
D.S. Pratt, T.A. Knox, J. Erban.
Tamoxifen-induced steatohepatitis.
Ann Intern Med, 123 (1995), pp. 3
[10.]
Agraval, Zelkonitz.
Bone «flave», hypercalcemia and jaundice after tamoxifen therapy.
Arch Intern Med, 141 (1981), pp. 1240
[11.]
A.M. Blackburn, S.A. Amiel, R.R. Millis, R.D. Rubens.
Tamoxifen and liver damage.
BMJ, 289 (1984), pp. 288
[12.]
P. Riippa, A. Kauppila, H. Sundstrom, R. Vihko.
Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma.
Anticancer Res, 4 (1984), pp. 109-112
[13.]
L. Bressollette, H. Swirsky, D. Kernaleguen, D. Carlhant, F. Fauquert, M.A. Lebot, et al.
Hépatite au cours d'un traitement au tamoxifène.
Therapie, 44 (1989), pp. 151
[14.]
M. VanHoof, J. Rahier, Y. Horsmans.
Tamoxifen-induced steatohepatitis.
Ann Intern Med, 124 (1996), pp. 855-856
[15.]
M. Noguchi, T. Taniya, K. Tajiri, K. Miwa, I. Miyazaki, H. Koshino, et al.
Fatal hyperlipaemia in a case of metastatic breast cancer traeted by tamoxifen.
Br J Surg, 74 (1987), pp. 586-587
[16.]
Y. Ogawa, Y. Murata, A. Nishioka, T. Inomata, S. Yoshida.
Tamoxifen-induced fatty liver in patients with breast cancer.
[17.]
G.N. Loomus, P. Aneja, R.A. Bota.
A case of peliosis hepatis in association with tamoxifen therapy.
Am J Clin Pathol, 80 (1983), pp. 881-882
[18.]
B. Fisher, J. Dignam, J. Bryant, A. DeCillis, D.L. Wickerham, N. Wolmark, et al.
Five versus mores than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
J Natl Cancer Inst, 88 (1996), pp. 1529-1542
[19.]
M. Duhn, A.M. Walker, K.H. Kronlund.
Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.
Pharmacoepidemiology and Drug Safety, 8 (1999), pp. 275-283
[20.]
Swedish Breast Cancer Cooperative Group.
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.
J Natl Caner Inst, 88 (1996), pp. 1543-1549
[21.]
Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group.
Preliminary results from the Cancer Research Campaign Trial evalluating tamoxifen duration in women aged fifty years or olfder with breast cancer.
J Natl Cancer Inst, 88 (1996), pp. 1834-1839
[22.]
Early Breast Cancer Trialists' Collaborative Group.
Tamoxifen for early breast cancer: an overview of the randomised trials.
Lancet, 351 (1998), pp. 1451-1467
[23.]
D.C. Tormey, R. Gray, H.C. Falkson.
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Easteran Cooperative Oncology Group.
J Natl Cancer Inst, 88 (1996), pp. 1828-1833
[24.]
J.J. Dignam, J. Bryant, H.S. Wieand, B. Fisher, N. Wolmark.
Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.
Control Clin Trials, 19 (1998), pp. 575-588
[25.]
B. Fisher, J. Dignam, J. Bryant, N. Wolmark.
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
J Natl Cancer Inst, 93 (2001), pp. 662-664
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/S0210-5705(23)00171-1
No mostrar más